Cointime

Nucleix

company

About

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests.

  • 11 - 50

Highlights

Total Funding Amount
$55M
Funding Rounds
1
Investors
2

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$55M
Industries
Biotechnology,Health Care,Information Technology,Manufacturing,Medical Device,Personal Health
Founded date
Jan 1, 2008
Number Of Employee
11 - 50
Operating Status
Active

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns.

Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$55M
Nucleix has raised a total of $55M in funding over 2 rounds. Their latest funding was raised on Apr 7, 2021 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 7, 2021 Series Unknown $55M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
Nucleix is funded by 2 investors. OCI Bio Investments and Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
OCI Bio Investments — Series Unknown
Lilly Asia Ventures — Series Unknown
Cointime
เนื้อหา
บริษัท